Comparison of Efficacy and Tolerability of Fulvestrant+Placebo vs Fulvestrant+Palbociclib as First Line Therapy for Postmenopausal Women With HR+ Metastatic BC Treated With 5 Years of Hormonal Therapy Remaining Disease Free More Than 12 Months After Completion or Have de Novo Metastatic Disease
Condition: Breast NeoplasmsInterventions: Drug: PD-0332991 (Palbociclib); Drug: Fulvestrant; Drug: PlaceboSponsors: Spanish Breast Cancer Research Group; AstraZenecaRecruiting - verified March 2016
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials